Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Deferred tax assets — Capitalized R&D / IPR&D by Year
Deferred tax assets — Capitalized R&D / IPR&D ($M) ($M)
Vertex Pharmaceuticals Deferred tax assets — Capitalized R&D / IPR&D: $1,921M in FY2025, up 36.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets — Capitalized R&D / IPR&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,921 | +36.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,404 | +52.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 919 | +109.7% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 438 | – | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2023-02-10) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Deferred tax assets — Capitalized R&D / IPR&D ($M), annual FY2021–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/dta-iprd
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.